Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0509. 2009 Authors' conclusions Eculizumab (Soliris®) is recommended for restricted use within NHS Wales according to agreed guidelines for the treatment of paroxysmal nocturnal haemoglobinuria.
AWMSG is of the opinion that eculizumab (Soliris®) is not suitable for shared care within NHS Wales. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Hemoglobinuria, Paroxysmal; Humans Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000414 Date abstract record published 08/08/2012 |